We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

83 hedge funds and large institutions have $206M invested in Applied Therapeutics in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,082% more call options, than puts

Call options by funds: $26.4M | Put options by funds: $510K

700% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 4

145% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 11

93% more capital invested

Capital invested by funds: $107M → $206M (+$99M)

51% more funds holding

Funds holding: 5583 (+28)

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

11.56% more ownership

Funds ownership: 68.08%79.64% (+12%)

Holders
83
Holders Change
+28
Holders Change %
+50.91%
% of All Funds
1.21%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
32
Increased
27
Reduced
11
Closed
4
Calls
$26.4M
Puts
$510K
Net Calls
+$25.9M
Net Calls Change
+$6.01M
Name Holding Trade Value Shares
Change
Change in
Stake
SCM
26
Soleus Capital Management
Connecticut
$1.54M -$1.82M -731,833 -61%
LCM
27
Laurion Capital Management
New York
$1.44M +$212K +85,106 +25%
WVP
28
Worth Venture Partners
New Jersey
$1.38M +$545K +219,008 +113%
Two Sigma Investments
29
Two Sigma Investments
New York
$958K +$539K +216,646 +312%
Marshall Wace
30
Marshall Wace
United Kingdom
$865K +$642K +258,144 New
Citigroup
31
Citigroup
New York
$737K +$383K +153,950 +233%
BCM
32
Bridgeway Capital Management
Texas
$649K +$124K +50,000 +35%
Qube Research & Technologies (QRT)
33
Qube Research & Technologies (QRT)
United Kingdom
$649K +$463K +186,123 +2,465%
EI
34
EAM Investors
California
$613K -$519K -208,725 -53%
Man Group
35
Man Group
United Kingdom
$558K +$414K +166,550 New
State Street
36
State Street
Massachusetts
$471K +$8.46K +3,400 +2%
Jane Street
37
Jane Street
New York
$442K -$177K -71,273 -35%
RB
38
Richmond Brothers
Michigan
$414K
UBS Group
39
UBS Group
Switzerland
$403K +$29.4K +11,826 +11%
Morgan Stanley
40
Morgan Stanley
New York
$359K +$139K +55,875 +109%
Northern Trust
41
Northern Trust
Illinois
$357K +$19K +7,650 +8%
6CM
42
683 Capital Management
New York
$338K +$251K +100,806 New
XT
43
XTX Topco
Cayman Islands
$273K +$203K +81,371 New
CCM
44
Connective Capital Management
California
$265K +$197K +79,242 New
Citadel Advisors
45
Citadel Advisors
Florida
$260K +$192K +77,239 +20,708%
Simplex Trading
46
Simplex Trading
Illinois
$241K +$179K +71,991 New
CSS
47
Cubist Systematic Strategies
Connecticut
$196K +$135K +54,085 +1,199%
Two Sigma Advisers
48
Two Sigma Advisers
New York
$171K +$88.1K +35,400 +227%
MS
49
Maven Securities
Jersey
$168K +$124K +50,000 New
JP Morgan Chase
50
JP Morgan Chase
New York
$157K +$116K +46,545 +11,996%

APLT Hedge Fund Activity: Q4 2023 in Review

83 of the 6,862 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q4 2023, worth a combined $206M — up 93% from $107M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new APLT positions and 4 closed out — a net gain of 28 holders — while 27 added to existing stakes and 11 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $10.2M. The largest seller was Armistice Capital, exiting entirely with an estimated $8.47M sold.

  • 83 institutional investors held Applied Therapeutics (APLT) as of Q4 2023, up from 55 in Q3 2023.
  • Funds reported $206M of Applied Therapeutics stock for Q4 2023, up 93% quarter-over-quarter.
  • 32 funds opened new Applied Therapeutics positions in Q4 2023 and 4 closed out, a net change of +28 holders.
  • The largest Applied Therapeutics buyer in Q4 2023 was Perceptive Advisors, an estimated $10.2M added.
  • The largest Applied Therapeutics seller in Q4 2023 was Armistice Capital, an estimated $8.47M sold.

Based on aggregated 13F filings for Q4 2023.